Participants can access this live virtual event on Sunday, October 18, from 11:15 AM – 12:15 PM CDT.

Severe asthma, which affects approximately 5% to 10% of patients with asthma, is associated with increased risk of hospitalization from exacerbations, increased morbidity, and increased mortality. A greater understanding of type‐2 cytokine pathways driving asthma has enabled the development of biomarkers and identification of therapeutic targets. By better identifying asthma phenotypes and endotypes, drugs targeting specific cytokines can be used to achieve asthma control and reduce the burden of disease for patients with refractory symptoms despite standard treatment.

This Medscape virtual symposium will bring a patient case to life using an award-winning Virtual Patient Simulation platform, MedSims. During the virtual symposium, attendees will be uniquely engaged in the MedSims and be able to contribute to the direction of the patient journey at key decision points and vote on clinical actions followed by expert faculty feedback. This will help provide evidence-based management of patients with asthma through the identification of phenotypic profile and comorbidities, determination of severity and level of control, and selection of appropriate biologic therapy.